MedPath

Evaluation of Breast CT

Not Applicable
Completed
Conditions
Breast Cancer
Interventions
Device: computed tomography
Device: MRI
Registration Number
NCT00584233
Lead Sponsor
University of California, Davis
Brief Summary

The investigators have studied the potential of breast computed tomography (bCT) for breast imaging under an NIH-funded Biomedical Research Partnership (BRP) grant (R01 EB002138-10), and 4 breast CT scanners have been developed that have imaged over 600 women to date (under more than one IRB-approved protocol). The BRP grant cannot be renewed, and with this (resubmitted) R01 grant application, the investigators seek to finalize the investigators' research in breast CT - The specific aims have been significantly modified as a result of the first critique, and the investigators now focus on a narrower set of remaining issues.

This version of the protocol will add breast magnetic resonance imaging (MRI) to the experimental procedures.

Detailed Description

Clinical evaluation: Four hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will be recruited to undergo additional imaging prior to biopsy, including (research) pre-and post-contrast enhanced breast CT imaging of both breasts, as well as (standard, FDA approved) contrast enhanced breast MRI. The potential of non-contrast enhanced breast CT will be compared using receiver operating characteristic (ROC) methodology against mammography alone, as well as with mammography + tomosynthesis. The breast CT images (including both pre-and post-contrast images) will be compared using ROC methodology against standard-of-care contrast-enhanced MRI (which includes both non-contrast and contrast images). The results of the clinical trials proposed in this investigation should provide strong evidence in regards to the potential of breast CT for breast cancer screening in the normal risk and high risk populations.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
75
Inclusion Criteria
  • Age at least 35 years old
  • Diagnostic findings from prior mammography highly suggestive of breast malignancy (BI- RADS® category 4 or BI-RADS® category 5)
  • Not pregnant or breast-feeding
  • Ability to lie motionless for up to 5 minutes
Read More
Exclusion Criteria
  • Recent breast biopsy
  • History of moderate or severe reaction to contrast agent injection
  • History of Allergy to Iodine
  • History of multiple food and/or drug allergy
  • Currently taking Glucophage or Glucovance (Metformin)
  • History of Chronic Asthma
  • History of Diabetes Mellitus
  • Renal (kidney) disease, or solitary kidney
  • Recent lab tests showing elevated serum creatinine (≥ 1.5 mg/dL)
  • Recent lab tests showing estimated glomerular filtration rate (eGFR) ≤ 60 ml/minute
  • Positive urine pregnancy test or currently breast-feeding
  • Inability to understand the risks and benefits of the study
  • The standard MRI contraindications apply, including but not limited to: having a pacemaker or other implanted electronic device, metal foreign bodies within the eye, aneurysm clips, heart valve prosthesis, vascular stents, coils, intrauterine devices (IUDs), inferior vena cava (IVC) filters, gunshot wounds with retained bullet fragments.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Breast CT and Breast MRIcomputed tomographyFour hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will undergo pre- and post- contrast breast computed tomography and pre- and post- contrast magnetic resonance imaging.
Breast CT and Breast MRIMRIFour hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will undergo pre- and post- contrast breast computed tomography and pre- and post- contrast magnetic resonance imaging.
Primary Outcome Measures
NameTimeMethod
Comparison of Pre- and Post- Contrast Breast Computed Tomography With Pre- and Post- Contrast Magnetic Resonance Imaging.5 years

The specific quantitative endpoint of the analysis is the difference in area under the receiver operating characteristic curve (AUC) between contrast-enhanced breast CT (CE-bCT) and contrast-enhanced breast MRI (CE-bMRI).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UC Davis Medical Center

🇺🇸

Sacramento, California, United States

© Copyright 2025. All Rights Reserved by MedPath